Department of Pediatrics, Ajou University Hospital, Ajou University School of Medicine, Ajou University Hospital, San 5, Wonchon-dong, Yeongtong-gu, Suwon, 443-721, Korea.
Curr Diab Rep. 2020 Nov 27;20(12):78. doi: 10.1007/s11892-020-01361-5.
This review focuses on the complex interactions between hyperglycemia and bone fragility and the effects of antidiabetic medications on bone metabolism.
Type 2 diabetes (T2D) is associated with increased risk of bone fracture even in those with increased or normal bone mineral density (BMD). The pathophysiology of diabetic bone disease is not completely understood, but it is thought to be multifactorial and associated with complex cross talk among factors such as AGEs, IGF-1, enteric hormones, and pro-inflammatory cytokines. Treatment for T2D may have an impact on bone metabolism. Diabetic bone disease should be considered a serious complication of long-standing T2D.
本篇综述聚焦于高血糖与骨脆弱之间的复杂相互作用，以及降糖药物对骨代谢的影响。
2 型糖尿病（T2D）即使在骨密度增加或正常的患者中，也与骨折风险增加相关。糖尿病性骨病的病理生理学尚未完全阐明，但据认为是多因素的，并与 AGEs、IGF-1、肠激素和促炎细胞因子等因素之间的复杂串扰有关。T2D 的治疗可能会对骨代谢产生影响。糖尿病性骨病应被视为长期 T2D 的严重并发症。
